These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 16792685)

  • 1. Effects of alveolar macrophage depletion on liposomal vaccine protection against respiratory syncytial virus (RSV).
    Benoit A; Huang Y; Proctor J; Rowden G; Anderson R
    Clin Exp Immunol; 2006 Jul; 145(1):147-54. PubMed ID: 16792685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innate and adaptive cellular phenotypes contributing to pulmonary disease in mice after respiratory syncytial virus immunization and infection.
    Lee YT; Kim KH; Hwang HS; Lee Y; Kwon YM; Ko EJ; Jung YJ; Lee YN; Kim MC; Kang SM
    Virology; 2015 Nov; 485():36-46. PubMed ID: 26196232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
    Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.
    Garlapati S; Garg R; Brownlie R; Latimer L; Simko E; Hancock RE; Babiuk LA; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Vaccine; 2012 Jul; 30(35):5206-14. PubMed ID: 22713718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of airway eosinophil and neutrophil infiltration by alpha-galactosylceramide in a mouse model for respiratory syncytial virus (RSV) vaccine-augmented disease.
    Benoit AC; Huang Y; Maneewatchararangsri S; Tapchaisri P; Anderson R
    Vaccine; 2007 Nov; 25(45):7754-62. PubMed ID: 17920164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
    Huang Y; Cyr SL; Burt DS; Anderson R
    J Clin Virol; 2009 Apr; 44(4):287-91. PubMed ID: 19233722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular Immune Correlates Preventing Disease Against Respiratory Syncytial Virus by Vaccination with Virus-Like Nanoparticles Carrying Fusion Proteins.
    Lee YT; Ko EJ; Kim KH; Hwang HS; Lee Y; Kwon YM; Kim MC; Lee YN; Jung YJ; Kang SM
    J Biomed Nanotechnol; 2017 Jan; 13(1):84-98. PubMed ID: 29302248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
    Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ
    Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus.
    Valosky J; Hishiki H; Zaoutis TE; Coffin SE
    Clin Diagn Lab Immunol; 2005 Jan; 12(1):171-9. PubMed ID: 15643003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
    Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
    Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.
    Shafique M; Wilschut J; de Haan A
    Vaccine; 2012 Jan; 30(3):597-606. PubMed ID: 22120195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of mucosal and cellular immune response in mice by vaccination with respiratory syncytial virus DNA encapsulated with transfersome.
    Xu J; Ding Y; Yang Y
    Viral Immunol; 2008 Dec; 21(4):483-9. PubMed ID: 19115938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory syncytial virus-like nanoparticle vaccination induces long-term protection without pulmonary disease by modulating cytokines and T-cells partially through alveolar macrophages.
    Lee YT; Ko EJ; Hwang HS; Lee JS; Kim KH; Kwon YM; Kang SM
    Int J Nanomedicine; 2015; 10():4491-505. PubMed ID: 26203246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection.
    Kim S; Jang JE; Yu JR; Chang J
    Vaccine; 2010 May; 28(22):3801-8. PubMed ID: 20362203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.
    Martinez-Sobrido L; Gitiban N; Fernandez-Sesma A; Cros J; Mertz SE; Jewell NA; Hammond S; Flano E; Durbin RK; García-Sastre A; Durbin JE
    J Virol; 2006 Feb; 80(3):1130-9. PubMed ID: 16414990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine.
    Cyr SL; Jones T; Stoica-Popescu I; Burt D; Ward BJ
    Vaccine; 2007 Apr; 25(16):3228-32. PubMed ID: 17374422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engystol reduces onset of experimental respiratory syncytial virus-induced respiratory inflammation in mice by modulating macrophage phagocytic capacity.
    Wronski S; Dannenmaier J; Schild S; Macke O; Müller L; Burmeister Y; Seilheimer B; Müller M
    PLoS One; 2018; 13(4):e0195822. PubMed ID: 29672626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GM-CSF treatment prevents respiratory syncytial virus-induced pulmonary exacerbation responses in postallergic mice by stimulating alveolar macrophage maturation.
    Naessens T; Schepens B; Smet M; Pollard C; Van Hoecke L; De Beuckelaer A; Willart M; Lambrecht B; De Koker S; Saelens X; Grooten J
    J Allergy Clin Immunol; 2016 Mar; 137(3):700-9.e9. PubMed ID: 26560044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced immune protection by a liposome-encapsulated recombinant respiratory syncytial virus (RSV) vaccine using immunogenic lipids from Deinococcus radiodurans.
    Huang Y; Anderson R
    Vaccine; 2002 Feb; 20(11-12):1586-92. PubMed ID: 11858866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.